4.6 Review

New topics in bradykinin research

期刊

ALLERGY
卷 66, 期 11, 页码 1397-1406

出版社

WILEY
DOI: 10.1111/j.1398-9995.2011.02686.x

关键词

angioedema; bradykinin; C1 esterase inhibitor; icatibant

资金

  1. Shire Human Genetic Therapies Inc.
  2. Jerini AG
  3. Jerini AG/Shire Human Genetic Therapies Inc.

向作者/读者索取更多资源

Bradykinin has been implicated to contribute to allergic inflammation and the pathogenesis of allergic conditions. It binds to endothelial B-1 and B-2 receptors and exerts potent pharmacological and physiological effects, notably, decreased blood pressure, increased vascular permeability and the promotion of classical symptoms of inflammation such as vasodilation, hyperthermia, oedema and pain. Towards potential clinical benefit, bradykinin has also been shown to exert potent anti-thrombogenic, antiproliferative and antifibrogenic effects. The development of pharmacologically active substances, such as bradykinin receptor blockers, opens up new therapeutic options that require further research into bradykinin. This review presents current understanding surrounding the role of bradykinin in nonallergic angioedema and other conditions seen by allergists and emergency physicians, and its potential role as a therapeutic target.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据